Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
Top-line data from a Phase III study of Sufentanil NanoTab PCA System, from AcelRx Pharmaceuticals, shows that the primary efficacy...
Clinical results from a Phase III trial of Sufentanil NanoTab PCA System, from AcelRx Pharmaceuticals, for the treatment of moderate-to-severe...
Top-line data results demonstrating that the first of two pivotal placebo-controlled Phase III studies for sublingual Sufentanil NanoTab PCA (patient-controlled...
The Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the...
Top-line results of the Phase III clinical trial demonstrate that in treating Acute Pain, the Sufentanil NanoTab PCA System, from...
Top-line results from a placebo-controlled, dose-finding, Phase II study of sublingual sufentanil NanoTab for Acute Pain, ARX 04, from AcelRx...
AcelRx Pharmaceuticals announced that ARX 04 (sufentanil sublingual tablet, 30 µg) met primary and secondary endpoints in a multi-center, double-blind,...